Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Precision Immuno-Oncology Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Cancer Type (Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others)
5.2.2. By Treatment Type (Checkpoint Inhibitors, Car T cell Therapy, Cancer Vaccines, and others)
5.2.3. By Biomarker (PD-L1, BRCA, KRAS, EGFR, and others)
5.2.4. By End-user (Hospital & Clinics, Research Institutes, others)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. Asia Pacific Precision Immuno-Oncology Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Cancer Type
6.2.2. By Treatment Type
6.2.3. By Biomarker
6.2.4. By End-user
6.2.5. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Precision Immuno-Oncology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Cancer Type
6.3.1.2.2. By Treatment Type
6.3.1.2.3. By Biomarker
6.3.1.2.4. By End-user
6.3.2. India Precision Immuno-Oncology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Cancer Type
6.3.2.2.2. By Treatment Type
6.3.2.2.3. By Biomarker
6.3.2.2.4. By End-user
6.3.3. Australia Precision Immuno-Oncology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Cancer Type
6.3.3.2.2. By Treatment Type
6.3.3.2.3. By Biomarker
6.3.3.2.4. By End-user
6.3.4. Japan Precision Immuno-Oncology Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Cancer Type
6.3.4.2.2. By Treatment Type
6.3.4.2.3. By Biomarker
6.3.4.2.4. By End-user
6.3.5. South Korea Precision Immuno-Oncology Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Cancer Type
6.3.5.2.2. By Treatment Type
6.3.5.2.3. By Biomarker
6.3.5.2.4. By End-user
7. Europe Precision Immuno-Oncology Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Cancer Type
7.2.2. By Treatment Type
7.2.3. By Biomarker
7.2.4. By End-user
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Precision Immuno-Oncology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Cancer Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By Biomarker
7.3.1.2.4. By End-user
7.3.2. Germany Precision Immuno-Oncology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Cancer Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By Biomarker
7.3.2.2.4. By End-user
7.3.3. Spain Precision Immuno-Oncology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Cancer Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By Biomarker
7.3.3.2.4. By End-user
7.3.4. Italy Precision Immuno-Oncology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Cancer Type
7.3.4.2.2. By Treatment Type
7.3.4.2.3. By Biomarker
7.3.4.2.4. By End-user
7.3.5. United Kingdom Precision Immuno-Oncology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Cancer Type
7.3.5.2.2. By Treatment Type
7.3.5.2.3. By Biomarker
7.3.5.2.4. By End-user
8. North America Precision Immuno-Oncology Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Cancer Type
8.2.2. By Treatment Type
8.2.3. By Biomarker
8.2.4. By End-user
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States Precision Immuno-Oncology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Cancer Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By Biomarker
8.3.1.2.4. By End-user
8.3.2. Mexico Precision Immuno-Oncology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Cancer Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By Biomarker
8.3.2.2.4. By End-user
8.3.3. Canada Precision Immuno-Oncology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Cancer Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By Biomarker
8.3.3.2.4. By End-user
9. South America Precision Immuno-Oncology Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Cancer Type
9.2.2. By Treatment Type
9.2.3. By Biomarker
9.2.4. By End-user
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Precision Immuno-Oncology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Cancer Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By Biomarker
9.3.1.2.4. By End-user
9.3.2. Argentina Precision Immuno-Oncology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Cancer Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By Biomarker
9.3.2.2.4. By End-user
9.3.3. Colombia Precision Immuno-Oncology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Cancer Type
9.3.3.2.2. By Treatment Type
9.3.3.2.3. By Biomarker
9.3.3.2.4. By End-user
10. Middle East and Africa Precision Immuno-Oncology Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Cancer Type
10.2.2. By Treatment Type
10.2.3. By Biomarker
10.2.4. By End-user
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Precision Immuno-Oncology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Cancer Type
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By Biomarker
10.3.1.2.4. By End-user
10.3.2. Saudi Arabia Precision Immuno-Oncology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Cancer Type
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By Biomarker
10.3.2.2.4. By End-user
10.3.3. UAE Precision Immuno-Oncology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Cancer Type
10.3.3.2.2. By Treatment Type
10.3.3.2.3. By Biomarker
10.3.3.2.4. By End-user
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Precision Immuno-Oncology Market: SWOT Analysis
14. Porter?s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Adaptimmune Therapeutics plc
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Agenus Inc
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Amgen Inc.
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. AstraZeneca plc
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. Bristol Myers Squibb Company
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Celgene Corporation
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. Eli Lilly and Company
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. F. Hoffmann-La Roche Ltd
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Gilead Sciences, Inc
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10. GlaxoSmithKline plc
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer